U.S. Water Utilities Stock News

NasdaqGS:ENVX
NasdaqGS:ENVXElectrical

Enovix (ENVX) Valuation Check As Operations Leadership Resets For Mass Battery Production

Enovix (ENVX) has reshaped its operations leadership as it prepares for mass production, with the planned retirement of its Chief Operating Officer and expanded roles for senior manufacturing executives focused on high-volume battery output. See our latest analysis for Enovix. The leadership reshuffle comes after a tough stretch for investors, with a 90 day share price return of a 45.78% decline and a 1 year total shareholder return of a 45.11% loss. This suggests sentiment has cooled even as...
OTCPK:UBAB
OTCPK:UBABBanks

United Bancorporation Of Alabama (OTCPK:UBAB) Margin Compression Challenges Bullish Earnings Narratives

United Bancorporation of Alabama (UBAB) closed out FY 2025 with fourth quarter revenue of about US$17.3 million and basic EPS of US$1.15, alongside trailing twelve month revenue of roughly US$69.7 million and EPS of US$5.23 that frame the latest numbers in a wider context. Over the past few quarters, revenue has ranged from about US$16.8 million to US$18.0 million while quarterly EPS has moved between US$1.15 and US$1.42, providing a clear view of how the income statement has been tracking...
OTCPK:FMBM
OTCPK:FMBMBanks

F And M Bank (OTCPK:FMBM) Margin Improvement To 22.5% Challenges Long Term Earnings Skepticism

F & M Bank (FMBM) has wrapped up FY 2025 with fourth quarter revenue of US$12.8 million and EPS of US$0.81, alongside trailing twelve month revenue of US$50.0 million and EPS of US$3.16 that reflect a 54.1% earnings gain over the past year versus a 6.8% per year earnings decline across the last five years. Over that period, revenue has moved from US$42.4 million and EPS of US$2.07 on a trailing basis in late 2024 to the latest trailing revenue of US$50.0 million and EPS of US$3.16, while the...
NYSE:ABBV
NYSE:ABBVBiotechs

Assessing AbbVie (ABBV) Valuation After Immunology Strength Offsets Humira Patent Hit

AbbVie (ABBV) is back in focus after its latest results showed immunology therapies like Skyrizi and Rinvoq offset the hit from Humira's patent expiration, pushing revenue above analyst estimates despite a miss on full-year EPS guidance. See our latest analysis for AbbVie. At a share price of $223.01, AbbVie has seen short term share price return softness over the past month alongside a 90 day share price return of 5.21%. Its 1 year total shareholder return of 25.34% and 5 year total...
NasdaqGM:ARRY
NasdaqGM:ARRYElectrical

Does Baird’s Downgrade of Array (ARRY) Hint at Deeper Questions Around Its Margin Resilience?

In late January 2026, Baird downgraded Array Technologies from Outperform to Neutral, citing valuation concerns and the risk that intensifying competition could pressure margins on future solar-tracker bookings. The move highlights a growing tension between analyst caution on profitability and investor optimism that Array Technologies can continue winning sizable project orders. We’ll now examine how this downgrade, and the concern over potential margin pressure, shapes Array Technologies’...
NYSE:JBL
NYSE:JBLElectronic

Should Jabil’s (JBL) Eagle Harbor Semiconductor Bet Require Action From Investors?

In January 2026, Jabil announced a minority investment and manufacturing collaboration with Eagle Harbor Technologies to combine its global production capabilities with EHT Semi’s advanced RF and pulsed DC power systems for next-generation semiconductor fabrication. This partnership gives Jabil direct exposure to highly specialized tools for high aspect ratio etch and atomic layer processes, tightening its link to leading-edge chip manufacturing flows. We’ll now look at how this...
NasdaqGS:GTLB
NasdaqGS:GTLBSoftware

Is It Time To Reassess GitLab (GTLB) After A 52% One-Year Share Price Slide

If you are wondering whether GitLab's current share price reflects its true worth, this article will walk through the numbers in a clear and practical way. GitLab's share price closed at US$34.98, with a 3.8% decline over 7 days, a 3.3% decline over 30 days, a 3.3% decline year to date, and a 51.9% decline over the past year. These figures may change how you think about its risk and potential. Recent coverage has focused on GitLab as a standalone DevOps platform and its role in helping...
NasdaqGS:AAPL
NasdaqGS:AAPLTech

Is Apple (AAPL) Pricing Fair After Recent Share Price Swings?

If you are wondering whether Apple stock still offers value at today's price, this article walks through the numbers so you can judge for yourself. Apple shares last closed at US$259.48, with returns of 4.6% over the past week, a 4.3% decline over the last month, and gains of 10.4% over 1 year, 70.5% over 3 years, and 94.6% over 5 years. These shifts in the share price sit against a backdrop of ongoing product cycles, ecosystem updates, and broader market moves that continue to keep Apple in...
NYSE:WBS
NYSE:WBSBanks

How Stronger Earnings, Lower Charge-offs, and Buybacks Will Impact Webster Financial (WBS) Investors

Webster Financial Corporation recently reported fourth-quarter and full-year 2025 results, showing higher net interest income and net income compared with the prior year, while its board declared past quarterly cash dividends of US$0.40 per common share and payments on Series F and Series G preferred stock scheduled for March and April 2026. An interesting angle for investors is that these earnings came alongside lower total net charge-offs than a year earlier and completion of a multi-year...
NYSE:BBT
NYSE:BBTBanks

Beacon Financial Merger Debut Highlights Scale, Integration Progress And New Dividend

Berkshire Hills Bancorp and Brookline Bancorp have completed their merger of equals to form Beacon Financial Corporation, trading as NYSE:BBT. The combined company reports a larger balance sheet, operational changes and ongoing integration efforts following the merger. Beacon Financial has also declared its first dividend as a newly merged entity. Beacon Financial, now trading at $28.35 under NYSE:BBT, is emerging from this merger as a larger regional player with an expanded footprint. The...
NYSE:TEVA
NYSE:TEVAPharmaceuticals

Teva (TEVA) Is Up 7.1% After 2025 Earnings Highlight Branded-Drugs Momentum And Pipeline Progress

Teva Pharmaceutical Industries reported its 2025 results on January 28, 2026, with revenue rising to US$17.26 billion and net income improving to US$1.41 billion, alongside continued momentum in branded drugs like AUSTEDO, UZEDY, and AJOVY. The earnings release underscored Teva’s ongoing shift from a primarily generics-focused business toward higher-margin innovative medicines, supported by cost savings initiatives and late-stage pipeline progress. We’ll now examine how Teva’s improving...
NYSE:RITM
NYSE:RITMMortgage REITs

A Look At Rithm Capital (RITM) Valuation As UBS Coverage And Deals Shape Expectations For Q4 Earnings

Interest around Rithm Capital (RITM) has picked up as investors look ahead to its fourth quarter 2025 results, expected revenue and earnings pressure in key segments, and fresh analyst coverage tied to recent acquisitions. See our latest analysis for Rithm Capital. Rithm Capital’s recent 1 day share price return of 8.22% decline and 7 day share price return of 7.13% decline, alongside heavier trading and fresh UBS coverage tied to the Paramount Group and Crestline deals, contrast with a 1...
NYSE:OXY
NYSE:OXYOil and Gas

How Rising WTI Prices And Mixed Earnings At Occidental Petroleum (OXY) Have Changed Its Investment Story

In recent months, Occidental Petroleum has seen its fortunes tied closely to rapidly rising WTI crude prices, even as its latest quarterly results showed lower revenue but adjusted earnings per share that exceeded analyst expectations. This combination of stronger oil prices, mixed financial performance and generally cautious analyst views is reshaping how investors weigh the company’s risk‑reward profile. With rising WTI crude prices as a key backdrop, we’ll now examine how these...
NYSE:UWMC
NYSE:UWMCDiversified Financial

CEO Mat Ishbia Trims UWM Stake As Valuation Risks Stay Elevated

UWM Holdings CEO Mat Ishbia has sold a large block of shares under a prearranged 10b5-1 trading plan. The transaction represents a substantial reduction in his indirect stake in NYSE:UWMC. Investors are watching the sale closely given ongoing pressure in the mortgage market. UWM Holdings, trading on the NYSE as UWMC, last closed at $4.91, with the stock showing an 11.3% gain over the past month and a 27.8% return over three years, while the one-year return stands at an 11.9% decline and the...
NasdaqCM:LTRX
NasdaqCM:LTRXCommunications

Lantronix (LTRX) Is Up 5.2% After AI-At-The-Edge Defense Pact With Safe Pro - Has The Bull Case Changed?

Lantronix Inc. and Safe Pro Group have entered into a Memorandum of Understanding and Master Services Agreement to co-develop Qualcomm-based, AI-powered edge compute solutions that enable real-time, on-device threat detection for drones and unmanned systems in defense and security applications. By pairing Lantronix’s rugged edge hardware with Safe Pro’s Object Threat Detection algorithms and integrating outputs into platforms like the U.S. Army’s ATAK, the alliance aims to embed autonomous...
NYSE:BY
NYSE:BYBanks

A Look At Byline Bancorp (BY) Valuation After Q4 Earnings Beat And Capital Return Moves

Why the latest earnings matter for Byline Bancorp (BY) Byline Bancorp (BY) is back in focus after fourth quarter results topped analyst expectations, accompanied by a 20% dividend increase and a fresh share repurchase authorization, even as management discussed ongoing pressure on margins and operating income. See our latest analysis for Byline Bancorp. Those fourth quarter earnings, the 20% dividend increase and the new buyback authorization come after a strong run, with a 90 day share price...
NasdaqGS:CHTR
NasdaqGS:CHTRMedia

Charter Communications (CHTR) Net Margin Near 9% Tests Bearish Earnings Narrative

Charter Communications (CHTR) just closed out FY 2025 with Q4 revenue of US$13.6b and basic EPS of US$10.47, alongside trailing twelve month revenue of US$54.8b and TTM EPS of US$36.90. Over the last few quarters, revenue has moved in a tight band from US$13.9b in Q4 2024 to between US$13.6b and US$13.8b through 2025. Quarterly EPS ranged from about US$8.50 to US$10.47, giving investors a clear view of how earnings track against fairly steady top line numbers. With a TTM net income of...
NYSE:KMI
NYSE:KMIOil and Gas

Will Record Q4 Results and a $10 Billion Gas Backlog Change Kinder Morgan's (KMI) Narrative

In January 2026, Kinder Morgan reported fourth-quarter 2025 sales of US$4,508 million and net income of US$996 million, alongside a 2% year-over-year increase in its quarterly dividend to US$0.2925 per share. The company also highlighted a gas-focused project backlog exceeding US$10 billion, underlining how recently sanctioned projects are reshaping its long-term earnings mix. We’ll now examine how Kinder Morgan’s record quarterly performance and expanding gas project backlog influence the...
NYSE:PIPR
NYSE:PIPRCapital Markets

A Look At Piper Sandler (PIPR) Valuation After Recent Share Price Softness

Event context and recent share performance Piper Sandler Companies (PIPR) has been on investors’ radar after recent share price moves, with the stock slipping about 0.3% in the latest session and 3.9% over the past week. See our latest analysis for Piper Sandler Companies. That recent 3.9% weekly share price decline comes after a steadier backdrop, with a 90 day share price return of 6.95% and a 1 year total shareholder return of 11.39%, so short term momentum looks softer than the longer run...
NYSE:NIC
NYSE:NICBanks

Assessing Nicolet Bankshares (NIC) Valuation After Strong Earnings And Higher Investor Optimism

Nicolet Bankshares (NIC) is back in focus after reporting fourth quarter and full year 2025 results, showing higher net interest income and net income, alongside a fresh shareholder approval to increase authorized shares. See our latest analysis for Nicolet Bankshares. After these earnings and the shareholder approval to increase authorized shares, Nicolet Bankshares’ share price has climbed to US$145.98, with a 21.16% year to date share price return and a 31.47% total shareholder return over...
NasdaqGS:NTCT
NasdaqGS:NTCTCommunications

Assessing NetScout Systems (NTCT) Valuation After New nGeniusONE Wi Fi 7 And Security Capabilities

NetScout Systems (NTCT) is back in focus after unveiling new nGeniusONE capabilities that target Wi-Fi 7 observability and SSL/TLS certificate monitoring, raising fresh questions about how the stock reflects its role in digital resilience. See our latest analysis for NetScout Systems. The new nGeniusONE features land at a time when NetScout Systems’ share price is US$27.81, with a 30 day share price return of 3.58% and a 1 year total shareholder return of 16.65%. By comparison, the 3 and 5...
NasdaqGS:MRNA
NasdaqGS:MRNABiotechs

Moderna Rare Disease Deal And Leadership Shift Raise Valuation Questions

Moderna (NasdaqGS:MRNA) announced a global collaboration and license agreement with Recordati to develop and commercialize its investigational mRNA therapy, mRNA-3927, for propionic acidemia. The company also shared a leadership change, with David Berman appointed as Chief Development Officer as Moderna focuses on new mRNA-based therapies. For you as an investor, this marks a clear move by Moderna to build out its rare disease pipeline alongside its existing mRNA vaccine work. The agreement...
NasdaqGS:MSTR
NasdaqGS:MSTRSoftware

Why Strategy (MSTR) Is Down 8.2% After Leveraged Bitcoin Treasury Expansion And What's Next

In recent days, Strategy Inc. continued expanding its bitcoin treasury, adding 2,932 BTC for about US$264.10 million and lifting its holdings to roughly 712,647 BTC, while funding purchases through common and preferred stock offerings. At the same time, the company’s bitcoin-centric capital framework, with vehicles ranging from common shares to high-yield preferred stock, has intensified debate over leverage, dividend sustainability, and its role as a proxy for direct bitcoin...
NasdaqGM:OCUL
NasdaqGM:OCULPharmaceuticals

Ocular Therapeutix Leadership Shifts And Valuation Gap Draw Investor Focus

Ocular Therapeutix (NasdaqGM:OCUL) announced that its Chief Financial Officer has taken a temporary medical leave. The company named an interim CFO to oversee finance and operations during the leave. Ocular Therapeutix also appointed an experienced industry executive as Global Chief Commercial Officer. The new commercial leader has a background in launching ophthalmic products at large pharmaceutical companies. For investors watching Ocular Therapeutix at a share price of $9.14, these...